Cardiovascular safety of testosterone therapy-Insights from the TRAVERSE trial and beyond: A position statement of the European Expert Panel for Testosterone Research.

The TRAVERSE trial provided robust evidence that testosterone therapy does not significantly increase the risk of major adverse cardiovascular events (MACE) in hypogonadal men.

• The TRAVERSE trial was described as a 'large-scale, randomized, placebo-controlled study'
• The trial findings align with previous meta-analyses that concluded testosterone therapy is safe and does not increase cardiovascular risk
• These findings informed recent United States Food and Drug Administration label changes for testosterone products

Hypogonadism itself is associated with increased cardiovascular and metabolic risks, providing context for evaluating testosterone therapy's cardiovascular profile.

• Testosterone therapy aims to restore testosterone levels in men with hypogonadism, 'a condition associated with increased cardiovascular and metabolic risks'
• Early research produced mixed results, with some studies suggesting potential increases in cardiovascular events such as myocardial infarction and stroke
• Other earlier studies indicated possible cardiovascular benefits, particularly in men with coexisting conditions like metabolic syndrome and type 2 diabetes

Testosterone therapy was found to effectively mitigate anemia in hypogonadal men, representing a dual benefit of increasing red blood cell production while managing cardiovascular risks.

• The anemia benefit was identified within the TRAVERSE trial findings
• The paper characterizes this as 'a dual benefit of increasing red blood cell production while managing cardiovascular risks'
• Current guidelines recommend monitoring hematocrit levels, indicating that erythropoietic effects require surveillance

Testosterone therapy offers significant clinical benefits including improved sexual function, mood, muscle mass, and bone density in men with hypogonadism.

• These benefits are listed as making testosterone therapy 'a cornerstone treatment for men with hypogonadism'
• Historical cardiovascular safety concerns had 'tempered its use' despite these benefits
• The panel concluded that 'the potential benefits outweighing the risks when the therapy is used responsibly'

There is expert consensus that testosterone therapy is cardiovascularly safe when prescribed to appropriately selected patients with regular monitoring.

• The position statement was produced by the European Expert Panel for Testosterone Research
• Current guidelines recommend 'individualized treatment plans with careful monitoring, especially of hematocrit levels'
• The panel stated 'there is consensus that testosterone therapy, when prescribed to appropriately selected patients and monitored regularly, is safe from a cardiovascular standpoint'
• The position statement 'amalgamates previous knowledge with current data and is in agreement with recent United States Food and Drug Administration label changes for testosterone products'